This study is the first step in a clinical research program that aims to study the immune response to influenza vaccine in the elderly and then to propose a new method of administering the vaccine. Influenza can cause severe complications in patients at risk (elderly and subjects vulnerable because of a chronic underlying disease). Over 90% of deaths related to influenza occur in people aged over 65 years. Vaccination is the most effective way to prevent infection. The World Health Organization recommends annual immunization for people at risk, including all persons aged over 65 years, to reduce the risk of morbidity and mortality related to influenza. However, the immune response to influenza vaccine appears to be lower in elderly than in young people.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
750
Blood sample of 7 ml
Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie
Pierre-Bénite, France
RECRUITINGantibody rates after influenza vaccination
Time frame: up to 3 months after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.